secwatch.observer — SEC 8-K summary
======================================

Issuer:     AVENUE THERAPEUTICS, INC. (ATXI)
CIK:        0001644963
Form:       8-K
Filed at:   2022-09-30T23:59:59+00:00
Accession:  0001104659-22-104616
Event type: regulatory
Sentiment:  neutral
Materiality: 0.65
Item codes: 3.01
LLM model:  deepseek-v4-flash:cloud@v2

Nasdaq Panel grants Avenue Therapeutics extension to Oct 31 to meet equity requirement, Oct 6 for bid price
--------------------------------------------------------------------------------

- Nasdaq Hearings Panel granted continued listing through Oct 31, 2022 to demonstrate compliance with stockholders' equity minimum of $2.5M.
- Company must also satisfy minimum bid price of $1.00 per share by Oct 6, 2022.
- Previously, Company was non-compliant with both Nasdaq Listing Rules 5550(a)(2) and 5550(b)(1).
- Hearing request on Aug 16, 2022 stayed suspension until Panel decision on Sep 29.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1644963/000110465922104616/0001104659-22-104616-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1644963/000110465922104616/tm2227168d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-104616

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer